Abiopharma

🔍 Truong Kristina (Executive)

Company: Enovix Corp (ENVX)

Report Date: 2026-04-01

Detailed Transactions and Holdings:

• Sold 2,220 shares of Common Stock at $4.97 per share (Direct)
  Date: 2026-04-01 | Code: F | equity_swap_involved: 0 | shares_owned_after: 216,136.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 638 shares of Common Stock at $5.06 per share (Direct)
  Date: 2026-04-05 | Code: F | equity_swap_involved: 0 | shares_owned_after: 215,498.00 | transaction_form_type: 4 | Footnotes: F1, F3

Footnotes:

• F1: Reflects the withholding of shares of the Issuer's common stock to satisfy tax withholding obligations in connection with the vesting of restricted stock units ("RSUs").
• F2: Includes 130,643 shares issuable upon the vesting and settlement of RSUs granted to the Reporting Person, as well as the following vested performance restricted stock units ("PRSUs"): (i) 2,489 PRSUs, which will be released to the Reporting Person in March 2027, and (ii) an aggregate of 35,278 PRSUs, 50% of which will be released in April 2027, with the remainder to be released in April 2028 (the foregoing PRSUs collectively referred to as the "Earned PRSUs"). Each PRSU represents a contingent right to receive one share of the Issuer's common stock upon settlement.
• F3: Includes 129,439 shares issuable upon the vesting and settlement of RSUs granted to the Reporting Person, as well as the Earned PRSUs.